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Summary
Despite the abundance of attention that cancer has attracted, it continues to consti-
tute one of the deadliest scourges of the modern era. Tumour heterogeneity greatly con-
tributes to the ineffectiveness of current therapies and hampers the study and treatment 
of cancer. There are two models accounting for tumour heterogeneity and propagation, 
namely clonal evolution model and cancer stem cell model. In particular, cancer stem 
theory has attracted much attention lately, as these cells with self-renewal and differen-
tiation abilities are responsible for the initiation of tumour development, growth, and 
its ability to metastasize and reoccur, and provide a reasonable explanation for poor 
prognosis for patients in advanced stages of solid tumours. Advances in technologies 
such as proteomics open new avenues in metastasis research by specifically revealing 
complex protein networks involved in tumour progression, which should facilitate early 
diagnosis and provide the basis for designing more effective treatment strategies.
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Introduction to the clonal evolution model and the cancer stem cell model
Despite the abundance of attention that cancer has attracted, it continues to 
constitute one of the deadliest scourges of the modern era. Although technolo-
gical improvements in screening modalities have facilitated detection of smaller 
tumours, current therapies for most types of cancer often fail. One of the rea-
sons for this certainly lies in the specific feature of cancer cells to uncontrollably 
grow and divide (Figure 1). In addition, common characteristic of all cancers 
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is striking variability among the cancer cells within a single tumour, whereby 
these cells differ in features such as size, morphology, antigen expression and 
membrane composition, as well as behavioural properties such as proliferation 
rate, cell‑cell interaction, metastatic proclivity, and sensitivity to chemo therapy 
[1‑3. This tumour heterogeneity contributes to the ineffectiveness of current the-
rapies and hampers the study and treatment of cancer, because tumour samples 
may not be representative of the whole and because its origins are not comple-
tely known [3,4]. 
There are two models that account for tumour heterogeneity and propaga-
tion: clonal evolution model and cancer stem cell model. According to the mo-
del of clonal evolution, cancer is formed through the accumulation of genetic 
changes in cells and gradual selection of clones [5]. The majority of therapeutic 
approaches (i.e. conventional therapies) based on the elimination of tumour ce-
Figure 1. Cancer cell fate. Cancer cells have a selective growth advantage over adjacent normal 
cells and acquire uncontrolled proliferation during tumorigenesis (e.g. resistance to apoptosis). 
Further on, metastasis process occurs that according to clonal theory involve invasion and ang-
iogenesis, migration and arrest in the capillary beds of distant organs.
15
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lls are based on this theory [6]. According to this model, tumour is induced 
after multiple mutations occur in a random single cell, conferring it a selective 
growth advantage over adjacent normal cells [3]. As the tumour further deve-
lops, genetic instability and uncontrolled proliferation facilitate the production 
of cells with additional mutations and hence new characteristics, such as resi-
stance to apoptosis. Therefore, increased proliferative capacity of cancer cells is 
the result of accumulated genetic mutations that enhance cellular proliferation 
or suppress normal growth inhibitory mechanisms and programmed cell death 
(apoptosis) [7]. The two main types of genes that play a key role in cancer deve-
lopment are oncogenes and tumour suppressor genes. Oncogenes are mutated 
forms of normal cellular genes generally involved in promoting cell prolifera-
tion, whereas tumour suppressor genes normally regulate proliferation in the 
way to stop it when necessary. Tumour suppressor gene products typified by 
p53 are frequently transcription factors that suppress mitosis and cell growth to 
allow for DNA repair. Nearly half of all cancers involve altered p53 genes. Other 
suppressor genes include Rb (retinoblastoma family), APC (adenomatous poly-
posis coli), SMAD4, TP53, p16/CDKN2A and BRCA (breast cancer susceptibility 
protein) types 1 and 2. Cancer results from cumulative mutations of oncogenes 
and tumour suppressor genes, which together allow the unregulated growth of 
cells. Oncogenes are typically dominant because they provide gain‑of‑functi-
on, whereas tumour suppressor genes are recessive and contain loss‑of function 
mutations. Both copies of a suppressor gene need to mutate to cause loss‑of‑
suppressor function, whereas only one copy of oncogene needs to mutate for 
gain‑of‑function. 
Poor outcomes of current therapies, in particular poor prognosis for pati-
ents in advanced stages of solid tumors, opened the possibility that tumor ce-
lls include a population of cells responsible for the initiation of tumor develo-
pment, growth, and its ability to metastasize and reoccur. Because these cells 
share some similarities with stem cells, they are referred to as cancer stem cells 
(CSCs). Cancer stem cells (CSCs) are rare tumor cells that have the potential to 
proliferate, self‑renew and induce tumorigenesis. Their self‑renewal and diffe-
rentiation abilities lead to the production of all tumor cell types, thereby genera-
ting tumor heterogeneity. Additionally, cancer stem cells are highly resistant to 
chemotherapy and radiation, probably due to the fact that cancer stem cells are 
quiescent and have high levels of ABC transporters, as well as great capacity for 
DNA repair and abundant anti‑apoptotic proteins [8]. Some additional specific 
features of CSCs include over‑expression of CD44, unknown status of cell cycle, 
deregulated self‑renewal signaling, perturbed adhesion/migration, and possibi-
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lity to be blocked in undifferentiated state [9]. Evidence for the existence of such 
cells was first proposed for haematological malignancies (leukaemia and multi-
ple myeloma) [10] and, more recently, for solid tumors, including breast, brain, 
prostate, head and neck, lung, skin, liver, ovary, colon and pancreatic cancer 
[11‑13]. When implanted into immune‑deficient mice, CSCs generate tumors that 
are identical to the parental tumors [14]. 
Major concept of CSCs model assumes that these cells arise from stem ce-
lls or progenitor cells (i.e. partially differentiated precursor cells with a limited 
proliferation capacity) [15]. According to the pre‑tumor progression hypothesis, 
the development of tumor results from the clonal evolution of the CSC popula-
tion [16]. The transformation of a normal stem cells into a cancer stem cell is the 
result of the accumulation of genetic aberrations (mutations in oncogenes, su-
ppressor genes and miss‑match repair genes) and epigenetic alterations (abnor-
mal methylation, histone modification) [15]. Several pivotal signaling pathways, 
including Wnt/β‑catenin, Hedgehog, and Notch pathways have been shown to 
play critical roles both in normal stem cells and cancer stem cells [17], and targe-
ting these signaling pathways in cancer stem cells might lay the groundwork for 
new, prospective approaches in future cancer treatment [8]. 
Molecular basis of metastasis 
The most deadly aspect of cancer is its ability to spread to other parts of the 
body through the blood and lymph systems in the process termed metastasis.
Metastasis is typically difficult to cure by standard surgical procedures, ra-
diation therapy, and chemotherapy, and confers poor prognosis for the affected 
patient. As a result, 90% of human cancer deaths are attributed to local invasion 
and distant metastases [18]. The molecular mechanisms involved in this process 
are not completely understood but those associated with vessel formation (angi-
ogenesis), cell attachment, invasion (matrix degradation, cell motility), and cell 
proliferation are generally accepted to be critical. The major molecular media-
tors of these processes are growth factor signaling molecules, chemokines, cell–
cell adhesion molecules (cadherins, integrins) as well as extracellular proteases 
(matrix metalloproteinases). 
Five major steps in metastasis process can be distinguished: 1. invasion and 
infiltration of surrounding normal host tissue with penetration of small lymp-
hatic or vascular channels; 2. release of neoplastic cells (either single cells or 
small clumps) into the circulation; 3. survival in the circulation; 4. arrest in the 
capillary beds of distant organs; and 5. penetration of the lymphatic or blood 
vessel walls followed by growth of the disseminated tumour cells [19].  
17
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Traditional models of metastasis have described a process in which genomic 
instability causes the genesis of rare sub‑populations of cells within the pri-
mary tumor that have acquired a metastatic phenotype [20,21]. This viewpoint 
was supported by the clinical observation that metastatic lesions are rare events 
despite the continual dissemination of significant numbers of tumor cells into 
the circulation [22,23]. However, recent gene expression profiling experiments 
have shown that paired primary tumors and metastases are similar, whereas a 
significant difference is observed when primary tumors with or without meta-
stases are compared [18,24‑26]. These studies challenged the theory that meta-
stasis‑capable cells are rare, and suggest that metastatic capacity is embedded 
in the majority of cells within the primary tumor and may be determined at an 
early stage of carcinogenesis. In the light of several recent experiments impli-
cating that only rare cancer‑initiating tumor stem cells are capable of forming 
distant metastasis at any significant rate [27,28], Molloy et al. [21] has postulated 
that non‑transformed stromal cells adjacent to primary tumor may contribute, 
at least partially, to the ‘metastasis’ signature seen in bulk tumor. Different in-
flammatory molecules such as cytokines, chemokines and growth factors are 
produced in the local tumor environment by different cells accounting for a 
complex cell interaction and regulation of differentiation, activation, function 
and survival of multiple cell types [29]. Chemokines, secreted by both, stromal 
and non‑tumor‑derived stem cells can act as positive mediators of metastasis 
in both, the microenvironment of the primary tumor by stimulating migration 
of tumor cells away from the area, as well as in the microenvironment of the 
distant organs by encouraging metastatic cell homing [21]. In addition, different 
growth factors secreted by stromal cells can also mediate tumor initiation and 
progression, e.g. epithelial growth factor (EGF), fibroblast growth factor (FGF), 
hepatocyte growth factor (HGF), insulin‑like growth factor (IGF), and transfor-
ming growth factor‑β (TGF‑β). The complex interaction between cytokines, che-
mokines, growth factors and their receptors forms an intricate network at the 
tumor site, which is primary responsible for an overall tumor progression and 
spreading. 
Short overview of proteomics technologies 
Most issues in modern cell biology have been tackled using the so called 
“reductionist methods”, i.e., by studying one gene, one protein or one specific 
protein modification at a time. This reductionism has been necessary, given the 
complexity of biological systems and lack of appropriate tools for developing 
more integrative methodologies. With the continuous development of techno-
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logy, it is now possible to get a more thorough understanding of complex biolo-
gical systems by simultaneous observation of their many characteristics. In this 
respect, proteomics has emerged as powerful approach that provides an insight 
into actual cellular processes. The term “proteome” was first coined in 1994 by 
an Australian scientist Marc Wilkins to describe the total set of proteins expre-
ssed in a given cell at a given time. The study of proteome or proteomics covers 
all aspects of protein properties on a large scale, including its level of expression, 
protein folding and 3‑D structure, function, protein interactions, cellular locali-
zation and the modifications, such as isoforms and post‑translational modifica-
tions. The analysis of proteins represents a challenge as their structure, function 
and expression could be controlled at many cellular regulatory points starting 
from transcription, mRNA splicing, translation and subsequent protein modi-
fications, such as the addition or removal of phosphate groups at specific sites, 
addition of carbohydrate chains (glycosylation), formation of protein complexes 
e.g. with lipids (HDL, LDL, VLDL), cellular translocation etc. [30]. While prote-
ome profiling is an important and necessary step for a complete understanding 
of the function of a protein complex, proteomics can also be applied to study 
global proteome function. Unlike genomes, proteomes are dynamic and many 
proteomic studies focus on examining changes in proteome composition under 
various conditions.
The main methodological approaches in proteomics research are “shotgun” 
approach and classical gel‑based approach. “Shotgun proteomics” refers to the 
direct liquid chromatography/mass spectrometry (LC‑MS) analysis of complex 
peptide mixtures derived from proteolytic digestion of heterogenous mixtures 
of proteins in order to rapidly reveal a global profile of the protein complement 
within the mixture. LC‑MS requires that the protein mixture be fractionated 
either in order to reduce complexity by targeted fractionation of peptides be-
aring specific chemical features (e.g. reactive sulfhydryl groups as at cysteine 
residues or phosphorylation caused by post‑translational modifications) or with 
the aim of increasing the potential of mass spectrometer to detect all peptides 
in the sample mixture [31]. The latter approach, commonly known as MudPIT 
(multi‑dimensional protein identification technique) is achieved by using seve-
ral sequential separation methods (usually microcapillary cation‑exchange and 
reverse‑phase chromatography) coupled with tandem mass spectrometry. 
Gel‑based approach relies on two‑dimensional gel electrophoresis (2‑DE) se-
paration of complex protein mixtures followed by mass spectrometric analysis 
of selected protein spots. In 2‑DE, proteins are first resolved by isoelectric focu-
sing according to their isoelectric points, and then according to their molecular 
19
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weights using sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
(SDS‑PAGE). At the core of most modern proteomic studies lies mass spectrome-
try (MS) [32]. Mass spectrometer consists of an ion source, a mass analyser that 
measures the mass‑to‑charge ratio (m/z) of the ionized analytes, and a detector 
that registers the number of ions at each m/z value. Electrospray ionization (ESI) 
and matrix‑assisted laser desorption/ionization (MALDI) are the ionization met-
hods most commonly used for protein and peptide samples. ESI generates ions 
directly from solution and is therefore coupled with liquid‑chromatographic 
(LC) or electrophoretic instrumentation. The sample is sprayed into a fine spray 
in the presence of an electric field. Charge accumulates on the sample droplets 
leading to their explosion due to mutual repulsion of charges and formation of 
ions. In MALDI, the sample is mixed with a UV‑absorbing matrix compound 
(e.g. α‑cyano‑4‑hydroxy‑trans-cinnamic acid, sinapinic acid) and crystallized. 
The mixture is then excited with a laser bringing about evaporation of the matrix 
compound, which carries the sample molecules into vapor phase. Sample ions 
are formed by the electrons and protons exchange with the matrix. MALDI‑MS 
is usually used to analyze relatively simple peptide mixtures, whereas ESI‑MS 
(LC‑MS) is the method of choice when it comes to the analysis of complex sam-
ple mixtures [32]. Recent advances in mass spectrometry and the determination 
of the complete genomic sequences of several organisms have greatly facilitated 
the application of proteomics to many research fields. 
One of the most important goals in proteomics is the ability to accurately 
measure quantitative changes in protein expression in response to a variety of 
internal and external stimuli [33]. Therefore, the development of methods that 
would allow accurate protein quantitation is currently one of the most challen-
ging aspects of proteomics. One of the most common methods used in quantita-
tive proteomics is introduction of a chemically equivalent differential mass tag 
that allows the comparative quantitation of proteins in one sample to another. 
The labels change the mass of a protein or peptide without affecting the anal-
ytical or biochemical properties [34]. Differential isotopic labels can be introdu-
ced metabolically, enzymatically or chemically, and, depending on the method 
used, at either the peptide or the protein level [33]. One of the most popular che-
mical labeling method is ICAT (isotope‑coded affinity tags), in which the stable 
isotopes are incorporated after isolation by selective alkylation of cysteines with 
either a heavy (d8) or light (d0) reagent [35]. The two protein mixtures are then 
mixed and digested with trypsin. ICAT‑labeled peptides are isolated by biotin‑
affinity chromatography and then analyzed by online HPLC coupled to a tan-
dem mass spectrometer. The ratio of the ion intensities for an ICAT‑ labeled pair 
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quantifies the relative abundance of its parent protein in the original cell state. 
In addition, the tandem mass spectrum reveals the sequence of the peptide and 
unambiguously identifies the protein [35]. 
DIGE (Difference Gel Electrophoresis) is a method that labels protein sam-
ples with fluorescent dyes before 2‑DE, enabling accurate analysis of differences 
in protein abundance between different samples. In DIGE, samples of interest 
are labeled with two (or three) spectrally distinct fluorescent dyes (Cy‑2, Cy‑3 
and Cy‑5) and run on the same gel. The three gel images corresponding to each 
of the Cy‑Dye scans are then superimposed to generate a spot map where paired 
spots within the same gel can be accurately quantified. 
Recently, SELDI‑TOF MS (Surface Enhanced Laser Desorption/Ionization Ti-
me‑of‑Flight Mass Spectrometry) has gained much appreciation in cancer rese-
arch for its ability to reveal potential diagnostic biomarkers in diverse complex 
biological specimens, such as serum, plasma, intestinal fluid, nipple aspirate 
fluid, urine, cell lysates, etc. The development of SELDI‑TOF MS has overcome 
limitations of other proteomic approaches in terms of the inability to analyze 
hundreds of samples within a short time, which is essential for obtaining bio-
logically and statistically relevant data. T his technique couples array‑based te-
chnology (ProteinChip®, Ciphergen Biosystems Inc.) with MALDI‑TOF MS. The 
protein chip arrays contain either chemically (anionic, cationic, hydrophobic, hy-
drophilic, or metal ion) or biochemically (immobilized antibody, receptor, DNA, 
enzyme, etc.) active surface, which retains proteins according to their specific 
physicochemical properties. After adding matrix solution to bound proteins, the 
latter are ionized with nitrogen laser and their molecular masses measured by 
TOF mass analyzer. As a result, unique protein abundance profiles of species bo-
und to the chip surface are obtained. Comparisons of spectra obtained from lar-
ge number of different samples reveal unique or over‑expressed protein signal 
in a particular sample set; however, this method determines the molecular mass 
of differentially abundant proteins rather than their identity. For more compre-
hensive overview of proteomics technologies, readers are referred to dedicated 
literature [33,36]. 
Recent advances in metastasis research using proteomics tools
Two‑dimensional gel electrophoresis (2‑DE) (Figure 2) followed by mass 
spectrometry‑based (MS) protein identification has been the most widely used 
proteomics method in the study of metastatic processes in diverse panel of 
cancers. By applying this approach, Wang et al. [37] found the CLIC1 protein 
(chloride intracellular channel 1) to be correlated with metastasis of gallbladder 
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carcinoma, the most frequent form of bile duct cancer, as its expression was si-
gnificantly up‑regulated in the highly metastatic gallbladder cancer GBC‑SD18H 
cell line when compared to the poorly metastatic GBC‑SD18L cell line. Similar-
ly, proteomics profiling of tumor tissues from gastric cancer revealed CLIC1 to 
be significantly up‑regulated in 67.9% of the patients [38]. This study has brou-
ght into relation the elevated expression of CLIC1 with lymph node metastasis, 
lymphatic invasion, perineural invasion, advanced pathological stage and poor 
survival in gastric cancer, and highlighted the role of CLIC1 in tumor invasion 
and metastasis in gastric cancer. Furthermore, comparative 2‑DE/MS analysis 
of two non‑small cell lung cancer cell lines with different metastatic potenti-
als identified unambiguously 33 differentially expressed proteins [39]. Among 
these, the over‑expression of S100A11 in non‑small cell lung cancer tissues was 
associated with higher tumor‑node‑metastasis stage and positive lymph node 
status, implying regulatory role of this protein in promoting invasion and me-
tastasis of non‑small cell lung cancer [39]. Involvement of this protein in me-
tastasis was also confirmed for other tumor types as well. For example, Song 
et al. [40] applied 2‑DE/MS approach towards analysis of metastasis‑associated 
proteins in human hepatocellular carcinoma (HCC) tissues. Among 16 differen-
tially expressed proteins including metabolic enzymes, subcellular trafficking 
Figure 2. Example of a 2-DE gel. 
The picture presents a gel ob-
tained by resolving total protein 
lysates from HEp-2 cells treated 
with metotrexate.
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proteins, chaperones and cytoskeletal regulating proteins, these authors  found 
S100A11 along with HSP27 and CK18 to be specifically connected with metasta-
sis of HCC. In addition, HSP27 was proposed as a useful therapeutic target not 
only for HCC, but also for other types of tumors, since its elevated levels were 
correlated with lymph node metastasis in breast and prostate cancer [40]. 
Besides 2‑DE, difference gel electrophoresis (DIGE) has proved a valuable 
tool in search of metastasis markers. A bright example is the study of lymph 
node metastatic prostate cancer (LNM PCa), which provided evidence that in-
creased expression of e‑FABP5, MCCC2, PPA2, Ezrin, and SLP2 and decreased 
expression of SM22 are useful diagnostic markers for the existence of LNM PCa 
[41]. The same authors also reported on the significantly higher levels of e‑FA-
BP5 in serum of patients with LNM PCa. e‑FABP5, whose over‑expression was 
previously established in prostate cancer tissues, induces invasion and metasta-
sis by up‑regulating the central player in the metastatic cascade, namely VEGF 
[42]. Besides e‑FABP5, ezrin has been recognized as a key component in tumor 
metastasis due to its unprecedented role as an integrator of  signals between 
metastasis‑associated cell surface molecules (Met receptor and CD44) and signal 
transduction components (Rho and Akt) [43]. 
Although many genes have the ability to inhibit both tumorigenesis and me-
tastasis, metastasis suppressor genes are unique in that they specifically block 
secondary tumor formation without affecting the primary tumor. Breast cancer 
metastasis suppressor 1 (BRMS1) is a protein with poorly understood molecular 
functions, whose over‑expression decreases the metastatic potential of human 
breast cancer and melanoma cells, whereas tumor cell lines with low levels of 
BRMS1 are highly metastatic. In order to unravel the role of BRMS1 in metastasis, 
Rivera et al [44] used the sensitive DIGE analysis coupled with MS to compare 
the protein expression profiles of wild‑type melanoma cells (WT), melanoma cells 
over‑expressing BRMS1 (Mel‑BRMS1), and melanoma cells in which endogeno-
us BRMS1 was silenced by a short hairpin RNA (sh635). Interestingly, more than 
75% of the identified proteins were down‑regulated in Mel‑BRMS1 cells compa-
red to WT, whereas all the identified proteins in sh635 cells extracts were up‑re-
gulated compared to WT indicating that transcriptional repression might be one 
of the functions of BRMS1, which might occur indirectly through interactions of 
BRMS1 with proteins in the transcriptional machinery [44]. Based on the seve-
ral identified proteins that regulate actin dynamics, the authors also proposed 
that BRMS1 might suppress metastasis in part by affecting cytoskeletal structures 
such as focal adhesions or lamellipodia. Furthermore, Nm23‑H1, the first meta-
stasis suppressor gene to be characterized, has been shown to alter both gene and 
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protein expression in cancer cells. To elucidate potential molecular mechanism by 
which Nm23‑H1 mediates metastasis suppression, Lee et al. [45] performed ICAT 
(isotope capture affinity tag) proteomic analysis on control and Nm23‑H1 stable 
transfected MDA‑MB 435 breast cancer cells. The ICAT data revealed that 189 and 
381 proteins were significantly down‑ and up‑regulated, respectively, upon over‑
expression of wild‑type Nm23‑H1. However, the most important finding of this 
study was identification of several proteins involved in RNA‑related functions, 
including GEMIN5, which plays a role in differential mRNA splicing. Based on 
obtained data, the authors propose that Nm23‑H1, through the regulation of RNA 
processing proteins, may play a role in proteome stability [45]. 
Maspin is a tumor‑suppressor protein that abolishes metastatic capacity in 
vivo of invasive mammary carcinoma cells [46]. Although this protein is the 
subject of intense study, the mechanisms by which maspin elicits its anti‑tu-
mor and anti‑metastatic effects are still the not completely clear. Chen et al. [47] 
successfully applied shotgun proteomics based on multidimensional protein 
identification technology (MudPIT) to compare the proteomes of maspin‑defici-
ent and maspin‑expressing tumor cells, and found that the expression of maspin 
has widespread effects on the tumor cell proteome. In most cases, protein expre-
ssion was affected without changes in mRNA levels, indicating that maspin has 
a significant influence on post‑transcriptional regulation of protein levels. This 
finding is probably a result of maspin’s effects on the expression and activity of the 
proteasome, which may be central to maspin’s tumor suppressor activity [47]. The 
same authors have showed that maspin causes significant alterations in proteins 
associated with the actin network (e.g. epithelial protein lost in neoplasm, gelso-
lin, etc.) necessary to support enhanced migratory ability of invasive cancer cells, 
and pro‑apoptotic proteins (e.g. protein phosphatase 2, Acinus, etc.). 
Proteomic profiling of serum and plasma is an emerging technique to iden-
tify new biomarkers indicative of disease severity and progression. In this res-
pect, SELDI‑TOF technology has emerged as a successful tool for obtaining me-
tastasis‑associated protein profiles for different cancer types including ovarian, 
breast, prostate, lung and colorectal cancer, as well as laryngeal squamous cell 
carcinoma (LSCC) [48‑51]. The most exciting aspect of all of these studies was 
actually the ability of SELDI‑TOF technology to accurately distinguish between 
patients with or without metastasis, which might have potential clinical use in 
diagnostic and prognostic purposes. However, clinically interesting study using 
this technology was recently presented by Gonçalves et al. [52], who performed 
SELDI‑TOF profiling of early postoperative serum from 81 high‑risk early breast 
cancer patients as to identify specific protein signature correlating with meta-
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static relapse. These authors found that postoperative serum proteomic profiles 
may indeed predict metastatic relapse in high‑risk primary breast cancer pa-
tients receiving adjuvant chemotherapy, providing the evidence that such an 
approach may have a significant prognostic value.
In conclusion, the emerging field of proteomics has opened many new chap-
ters in cancer research. In particular, such methodical approach holds great pro-
mise in everyday clinical practice, especially in monitoring disease progression 
and identifying high‑risk patients, which should facilitate early diagnosis and 
treatment of the patients (Figure 3). 
Figure 3. The ability to combine high-throughput genomic, proteomic, metabolomic and other 
experimental approaches with assays that address discovery of novel molecular mechanisms of 
cancer development and metastasis will eventually speed the emergence of safer, more effective 
and better-targeted therapeutic agents. Large scale (robotics) in vitro screening using representa-
tive cultured human cell lines (i.e. lymphoblast, fibroblast and epithelioid cells), and in vivo 
studies on “humanized” mouse models combined with functional genomic analysis of different 
organs might speed up both in vitro and in vivo testing.
25
Rad 508. Medical Sciences 35(2010) : 13-28
M. Sedić et al.: Unravelling New Pieces of Tumour Metastasis Puzzle: The Role of Proteomics
References
  [1] Ichim CV,Wells RA. First among equals: the cancer cell hierarchy. Leuk Lym-
phoma. 2006;47:2017‑27.
  [2] Axelson H, Fredlund E, Ovenberger M, Landberg G,Pahlman S. Hypoxia‑induced 
dedifferentiation of tumor cells‑‑a mechanism behind heterogeneity and ag-
gressiveness of solid tumors. Semin Cell Dev Biol. 2005;16:554‑63.
  [3] Campbell LL,Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal 
evolution? Cell Cycle. 2007;6:2332‑8.
  [4] Merlo LM, Pepper JW, Reid BJ,Maley CC. Cancer as an evolutionary and ecologi-
cal process. Nat Rev Cancer. 2006;6:924‑35.
  [5] Gil J, Stembalska A, Pesz KA,Sasiadek MM. Cancer stem cells: the theory and per-
spectives in cancer therapy. J Appl Genet. 2008;49:193‑9.
  [6] Clarke MF,Becker MW. Stem cells: the real culprits in cancer? Sci Am. 2006;295: 
52‑9.
  [7] Sarkar B, Dosch J,Simeone DM. Cancer stem cells: a new theory regarding a time-
less disease. Chem Rev. 2009;109:3200‑8.
  [8] Zhao RC, Zhu YS,Shi Y. New hope for cancer treatment: exploring the distinc-
tion between normal adult stem cells and cancer stem cells. Pharmacol Ther. 
2008;119:74‑82.
  [9] Besancon R, Valsesia-Wittmann S, Puisieux A, de Fromentel CC,Maguer-Satta V. 
Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem. 
2009;16:394‑416.
[10] Reya T, Morrison SJ, Clarke MF,Weissman IL. Stem cells, cancer, and cancer stem 
cells. Nature. 2001;414:105‑11.
[11] Ischenko I, Seeliger H, Schaffer M, Jauch KW,Bruns CJ. Cancer stem cells: how can 
we target them? Curr Med Chem. 2008;15:3171‑84.
[12] Marotta LL,Polyak K. Cancer stem cells: a model in the making. Curr Opin Genet 
Dev. 2009;19:44‑50.
[13] Bjerkvig R, Johansson M, Miletic H,Niclou SP. Cancer stem cells and angiogenesis. 
Semin Cancer Biol. 2009;19:279‑84.
[14] Akhtar K, Bussen W,Scott SP. Cancer stem cells ‑ from initiation to elimination, 
how far have we reached? (Review). Int J Oncol. 2009;34:1491‑503.
[15] Costa FF, Le Blanc K,Brodin B. Concise review: cancer/testis antigens, stem cells, 
and cancer. Stem Cells. 2007;25:707‑11.
[16] Calabrese P, Tavare S,Shibata D. Pretumor progression: clonal evolution of human 
stem cell populations. Am J Pathol. 2004;164:1337‑46.
[17] Grinstein E,Wernet P. Cellular signaling in normal and cancerous stem cells. Cell 
Signal. 2007;19:2428‑33.
Rad 508. Medical Sciences 35(2010) : 13-28
M. Sedić et al.: Unravelling New Pieces of Tumour Metastasis Puzzle: The Role of Proteomics
26
[18] Dong F, Budhu AS,Wang XW. Translating the metastasis paradigm from scien-
tific theory to clinical oncology. Clin Cancer Res. 2009;15:2588‑93.
[19] Chambers AF, Groom AC,MacDonald IC. Dissemination and growth of cancer cells 
in metastatic sites. Nat Rev Cancer. 2002;2:563‑72.
[20] Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis 
revisited. Nat Rev Cancer. 2003;3:453‑8.
[21] Molloy T,van ‘t Veer LJ. Recent advances in metastasis research. Curr Opin Genet 
Dev. 2008;18:35‑41.
[22] Wong IH, Leung T, Ho S, Lau WY, Chan M,Johnson PJ. Semiquantification of circu-
lating hepatocellular carcinoma cells by reverse transcriptase polymerase chain 
reaction. Br J Cancer. 1997;76:628‑33.
[23] Vona G, Estepa L, Beroud C, Damotte D, Capron F, Nalpas B, Mineur A, Franco D, 
Lacour B, Pol S, Brechot C,Paterlini-Brechot P. Impact of cytomorphological detec-
tion of circulating tumor cells in patients with liver cancer. Hepatology. 2004;39: 
792‑7.
[24] van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der 
Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley 
PS, Bernards R,Friend SH. Gene expression profiling predicts clinical outcome of 
breast cancer. Nature. 2002;415:530‑6.
[25] Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL,van’t Veer LJ. Gene expres-
sion profiles of primary breast tumors maintained in distant metastases. Proc 
Natl Acad Sci U S A. 2003;100:15901‑5.
[26] Weigelt B, Peterse JL,van ‚t Veer LJ. Breast cancer metastasis: markers and models. 
Nat Rev Cancer. 2005;5:591‑602.
[27] Jordan CT, Guzman ML,Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253‑
61.
[28] Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C,De Maria 
R. Identification and expansion of human colon‑cancer‑initiating cells. Nature. 
2007;445:111‑5.
[29] Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, Zhong H, 
Han B,Ferris RL. Intratumoral cytokines/chemokines/growth factors and tumor 
infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev. 2006;25: 
333‑56.
[30] Kraljevic S, Sedic M, Scott M, Gehrig P, Schlapbach R,Pavelic K. Casting light on 
molecular events underlying anti‑cancer drug treatment: what can be seen from 
the proteomics point of view? Cancer Treat Rev. 2006;32:619‑29.
[31] Patterson SD,Aebersold RH. Proteomics: the first decade and beyond. Nat Genet. 
2003;33 Suppl:311‑23.
[32] Aebersold R,Mann M. Mass spectrometry‑based proteomics. Nature. 2003;422: 
198‑207.
27
Rad 508. Medical Sciences 35(2010) : 13-28
M. Sedić et al.: Unravelling New Pieces of Tumour Metastasis Puzzle: The Role of Proteomics
[33] Elliott MH, Smith DS, Parker CE,Borchers C. Current trends in quantitative pro-
teomics. J Mass Spectrom. 2009;44:1637‑60.
[34] Iliuk A, Galan J,Tao WA. Playing tag with quantitative proteomics. Anal Bioanal 
Chem. 2009;393: 503‑13.
[35] Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH,Aebersold R. Quantitative analysis 
of complex protein mixtures using isotope‑coded affinity tags. Nat Biotechnol. 
1999;17:994‑9.
[36] Everley PA,Zetter BR. Proteomics in tumor progression and metastasis. Ann N Y 
Acad Sci. 2005;1059: 1‑10.
[37] Wang JW, Peng SY, Li JT, Wang Y, Zhang ZP, Cheng Y, Cheng DQ, Weng WH, Wu 
XS, Fei XZ, Quan ZW, Li JY, Li SG,Liu YB. Identification of metastasis‑associat-
ed proteins involved in gallbladder carcinoma metastasis by proteomic analy-
sis and functional exploration of chloride intracellular channel 1. Cancer Lett. 
2009;281:71‑81.
[38] Chen CD, Wang CS, Huang YH, Chien KY, Liang Y, Chen WJ,Lin KH. Overexpres-
sion of CLIC1 in human gastric carcinoma and its clinicopathological signifi-
cance. Proteomics. 2007;7:155‑67.
[39] Tian T, Hao J, Xu A, Luo C, Liu C, Huang L, Xiao X,He D. Determination of me-
tastasis‑associated proteins in non‑small cell lung cancer by comparative pro-
teomic analysis. Cancer Sci. 2007;98:1265‑74.
[40] Song HY, Liu YK, Feng JT, Cui JF, Dai Z, Zhang LJ, Feng JX, Shen HL,Tang ZY. 
Proteomic analysis on metastasis‑associated proteins of human hepatocellular 
carcinoma tissues. J Cancer Res Clin Oncol. 2006;132:92‑8.
[41] Pang J, Liu WP, Liu XP, Li LY, Fang YQ, Sun QP, Liu SJ, Li MT, Su ZL,Gao X. Profil-
ing protein markers associated with lymph node metastasis in prostate cancer 
by DIGE‑based proteomics analysis. J Proteome Res. 9:216‑26.
[42] Jing C, Beesley C, Foster CS, Chen H, Rudland PS, West DC, Fujii H, Smith PH,Ke 
Y. Human cutaneous fatty acid‑binding protein induces metastasis by up‑regu-
lating the expression of vascular endothelial growth factor gene in rat Rama 37 
model cells. Cancer Res. 2001;61:4357‑64.
[43] Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 
2004;10:201‑4.
[44] Rivera J, Megias D, Bravo J. Proteomics‑based strategy to delineate the molecular 
mechanisms of the metastasis suppressor gene BRMS1. J Proteome Res. 2007;6: 
4006‑18.
[45] Lee JH, Marshall JC, Steeg PS, Horak CE. Altered gene and protein expression by 
Nm23‑H1 in metastasis suppression. Mol Cell Biochem. 2009;329:141‑8.
[46] Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E,Sager 
R. Maspin, a serpin with tumor‑suppressing activity in human mammary epi-
thelial cells. Science. 1994;263:526‑9.
Rad 508. Medical Sciences 35(2010) : 13-28
M. Sedić et al.: Unravelling New Pieces of Tumour Metastasis Puzzle: The Role of Proteomics
28
[47] Chen EI, Florens L, Axelrod FT, Monosov E, Barbas CF, 3rd, Yates JR, 3rd, Felding-
Habermann B,Smith JW. Maspin alters the carcinoma proteome. FASEB J. 2005;19: 
1123‑4.
[48] Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA,Sadar MD. Identifica-
tion of serum amyloid A as a biomarker to distinguish prostate cancer patients 
with bone lesions. Clin Chem. 2005;51:695‑707.
[49] Nakagawa T, Huang SK, Martinez SR, Tran AN, Elashoff D, Ye X, Turner RR, Giu-
liano AE,Hoon DS. Proteomic profiling of primary breast cancer predicts axillary 
lymph node metastasis. Cancer Res. 2006;66:11825‑30.
[50] Zheng GX, Wang CX, Qu X, Deng XM, Deng BP,Zhang J. Establishment of serum 
protein pattern for screening colorectal cancer using SELDI‑TOF‑MS. Exp On-
col. 2006;28:282‑7.
[51] Cheng L, Zhou L, Tao L, Zhang M, Cui J,Li Y. SELDI‑TOF MS profiling of serum for 
detection of laryngeal squamous cell carcinoma and the progression to lymph 
node metastasis. J Cancer Res Clin Oncol. 2008;134:769‑76.
[52] Goncalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M, Bardou 
VJ, Houvenaegel G, Jacquemier J, Granjeaud S, Meng XY, Fung ET, Birnbaum D, Ma-
raninchi D, Viens P,Borg JP. Postoperative serum proteomic profiles may predict 
metastatic relapse in high‑risk primary breast cancer patients receiving adju-
vant chemotherapy. Oncogene. 2006;25:981‑9.
Sažetak
Novosti u mozaiku metastaziranja zloćudnih tumora
Unatoč napretku u istraživanju i proučavanju zloćudnih tumora, ta je bolest i dalje velik 
izazov modernoj medicini. Biološka raznolikost, ali i klasično poimanje mehanizama metasta-
ziranja tumora, razlog su neučinkovitosti postojećih načina liječenja. Dva su modela kojima se 
objašnjava ta raznolikost – model klonske evolucije te model matičnih stanica novotvorina. Ovaj 
drugi u posljednje je vrijeme privukao pozornost jer su matične stanice novotvorina, zbog svojih 
sposobnosti samostalnog obnavljanja i diferenciranja, odgovorne za nastanak i razvoj tumora te 
njihovu sposobnost metastaziranja i pojave recidiva. Metode globalnih analiza poput proteomike 
otvaraju nove mogućnosti u istraživanju procesa metastaziranja, jer omogućuju identifikaciju 
složenih mreža proteina uključenih u progresiju novotvorina, što može pridonijeti ranoj dijagno-
stici i omogućiti razvoj učinkovitijih lijekova protiv metastaza.
Ključne riječi: matične stanice novotvorevina; metastaziranje; proteomika
